Compare BHK & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHK | CSTL |
|---|---|---|
| Founded | 2001 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 655.1M | 722.8M |
| IPO Year | N/A | 2019 |
| Metric | BHK | CSTL |
|---|---|---|
| Price | $8.68 | $33.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $45.50 |
| AVG Volume (30 Days) | 246.3K | ★ 295.1K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 8.34% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | N/A | $2.42 |
| Revenue Next Year | N/A | $12.69 |
| P/E Ratio | $8.50 | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $8.69 | $17.72 |
| 52 Week High | $10.12 | $44.28 |
| Indicator | BHK | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 36.49 | 54.42 |
| Support Level | N/A | $22.88 |
| Resistance Level | $9.08 | $33.06 |
| Average True Range (ATR) | 0.08 | 1.24 |
| MACD | -0.03 | -0.42 |
| Stochastic Oscillator | 7.60 | 23.01 |
Blackrock Core Bond Trust is a closed-ended management investment company. Its objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing, under normal market conditions, at least 75% of its managed assets in bonds that are investment-grade quality at the time of investment. The trust, under a normal market scenario, will invest in a range of bonds, including corporate bonds, U.S. government and agency securities, and mortgage-related securities.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.